Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
1052 | 9585 | 32.1 | 59% |
Classes in level above (level 3) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
333 | 33297 | HUMAN SERUM ALBUMIN//CARDIOTOXICITY//BOVINE SERUM ALBUMIN |
Classes in level below (level 1) |
ID, lev. below | Publications | Label for level below |
---|---|---|
541 | 3252 | CARDIOTOXICITY//DEXRAZOXANE//DOXORUBICIN |
7594 | 1269 | MODIFIED ANTIBIOT//IDARUBICINOL//IDARUBICIN |
8042 | 1224 | PYRAZOLOACRIDINE//C 1311//IMIDAZOACRIDINONES |
8479 | 1180 | PIROXANTRONE//MITOXANTRONE//PIXANTRONE |
13527 | 766 | AN 9//SABARUBICIN//AN 7 |
13587 | 762 | HETERO ASSOCIATION//HETEROASSOCIATION//ACTINOMYCINS |
22966 | 306 | METHOXYMORPHOLINO DOXORUBICIN//AD 198//METHOXYMORPHOLINYL DOXORUBICIN |
24248 | 266 | MENOGARIL//ACLARUBICIN//BIOSYNTHESIS AND PROCESSING |
27422 | 188 | FLASH WAVE LIGHT//FLUOROVISUALIZATION//ARTHROBACTER PHOTOGONIMOS |
27652 | 184 | CNRS UPR 285//PHOTOSCI PHOTON CHEM SCI TECHNOL//PERI ANNELATION |
32734 | 103 | WARWICK ANALYT SCI//GELRED//DNA TOPOISOMERS |
33762 | 85 | ERYTHROID GENES//THERMOBIOL//ACLARUBICIN |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CARDIOTOXICITY | Author keyword | 288 | 37% | 7% | 634 |
2 | ANTHRACYCLINES | Author keyword | 170 | 38% | 4% | 355 |
3 | DOXORUBICIN | Author keyword | 145 | 15% | 9% | 865 |
4 | DEXRAZOXANE | Author keyword | 99 | 65% | 1% | 95 |
5 | ANTHRACYCLINE | Author keyword | 89 | 32% | 2% | 231 |
6 | ANTHRACYCLINE CARDIOTOXICITY | Author keyword | 58 | 88% | 0% | 28 |
7 | PYRAZOLOACRIDINE | Author keyword | 56 | 100% | 0% | 19 |
8 | ADRIAMYCIN | Author keyword | 42 | 17% | 2% | 218 |
9 | MITOXANTRONE | Author keyword | 39 | 19% | 2% | 181 |
10 | DOXORUBICINOL | Author keyword | 35 | 72% | 0% | 28 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CARDIOTOXICITY | 288 | 37% | 7% | 634 | Search CARDIOTOXICITY | Search CARDIOTOXICITY |
2 | ANTHRACYCLINES | 170 | 38% | 4% | 355 | Search ANTHRACYCLINES | Search ANTHRACYCLINES |
3 | DOXORUBICIN | 145 | 15% | 9% | 865 | Search DOXORUBICIN | Search DOXORUBICIN |
4 | DEXRAZOXANE | 99 | 65% | 1% | 95 | Search DEXRAZOXANE | Search DEXRAZOXANE |
5 | ANTHRACYCLINE | 89 | 32% | 2% | 231 | Search ANTHRACYCLINE | Search ANTHRACYCLINE |
6 | ANTHRACYCLINE CARDIOTOXICITY | 58 | 88% | 0% | 28 | Search ANTHRACYCLINE+CARDIOTOXICITY | Search ANTHRACYCLINE+CARDIOTOXICITY |
7 | PYRAZOLOACRIDINE | 56 | 100% | 0% | 19 | Search PYRAZOLOACRIDINE | Search PYRAZOLOACRIDINE |
8 | ADRIAMYCIN | 42 | 17% | 2% | 218 | Search ADRIAMYCIN | Search ADRIAMYCIN |
9 | MITOXANTRONE | 39 | 19% | 2% | 181 | Search MITOXANTRONE | Search MITOXANTRONE |
10 | DOXORUBICINOL | 35 | 72% | 0% | 28 | Search DOXORUBICINOL | Search DOXORUBICINOL |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ADRIAMYCIN | 213 | 21% | 9% | 910 |
2 | DOXORUBICIN CARDIOTOXICITY | 192 | 68% | 2% | 169 |
3 | INDUCED CARDIOTOXICITY | 178 | 47% | 3% | 283 |
4 | INDUCED CARDIOMYOPATHY | 155 | 47% | 3% | 247 |
5 | ADRIAMYCIN CARDIOTOXICITY | 154 | 75% | 1% | 111 |
6 | CARDIOTOXICITY | 153 | 25% | 5% | 519 |
7 | ANTHRACYCLINE INDUCED CARDIOTOXICITY | 150 | 65% | 1% | 143 |
8 | ANTHRACYCLINE CARDIOTOXICITY | 122 | 61% | 1% | 130 |
9 | DOXORUBICIN THERAPY | 112 | 63% | 1% | 112 |
10 | CARDIAC TOXICITY | 98 | 42% | 2% | 178 |
Journals |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ANTI-CANCER DRUG DESIGN | 9 | 11% | 1% | 71 |
2 | CARDIOVASCULAR TOXICOLOGY | 4 | 10% | 0% | 37 |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Doxorubicin-induced cardiomyopathy | 1998 | 845 | 35 | 74% |
Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity | 2004 | 1257 | 337 | 43% |
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies | 2012 | 119 | 149 | 72% |
Doxorubicin-Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy | 2014 | 29 | 195 | 70% |
Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron | 2009 | 204 | 138 | 85% |
Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer Chemotherapy | 2014 | 27 | 56 | 63% |
Anthracycline-induced cardiotoxicity | 1996 | 420 | 113 | 69% |
DOXORUBICIN CARDIOTOXICITY - ANALYSIS OF PREVAILING HYPOTHESES | 1990 | 477 | 42 | 88% |
Oxidative Stress, Redox Signaling, and Metal Chelation in Anthracycline Cardiotoxicity and Pharmacological Cardioprotection | 2013 | 38 | 273 | 79% |
Doxorubicin-induccd cardiomyopathy from the cardiotoxic mechanisms to management | 2007 | 239 | 157 | 61% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | MODIFIED ANTIBIOT | 27 | 74% | 0.2% | 20 |
2 | ROCKY MT CANC REHABIL | 14 | 55% | 0.2% | 18 |
3 | VALORISAT CHIM FINE | 12 | 52% | 0.2% | 17 |
4 | PHARMACEUT TECHNOL BIOCHEM | 11 | 16% | 0.6% | 59 |
5 | CNRS UPR 285 | 9 | 83% | 0.1% | 5 |
6 | HOSP PHARM YAMASHIMA KU | 6 | 100% | 0.0% | 4 |
7 | PHOTOSCI PHOTON CHEM SCI TECHNOL | 5 | 45% | 0.1% | 9 |
8 | MED BIOL UNIT | 4 | 44% | 0.1% | 7 |
9 | SHENZHEN ANTITUMOR DRUG DEV ENGN | 3 | 45% | 0.1% | 5 |
10 | CIR DRUG SCI | 3 | 50% | 0.0% | 4 |
Related classes at same level (level 2) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000016469 | DUOCARMYCINS//PYRROLOBENZODIAZEPINE//PYRROLE IMIDAZOLE POLYAMIDE |
2 | 0.0000014947 | DT DIAPHORASE//EO9//NQO1 |
3 | 0.0000010269 | P GLYCOPROTEIN//MULTIDRUG RESISTANCE//ABCG2 |
4 | 0.0000009338 | SHIKONIN//BETA LAPACHONE//PLUMBAGIN |
5 | 0.0000009223 | RESONANCE RAYLEIGH SCATTERING//RESONANCE LIGHT SCATTERING//DNA BINDING |
6 | 0.0000008544 | MEYERS INTERDISCIPLINARY ORGAN MED CHE//BLEOMYCIN HYDROLASE//BLEOMYCIN AMPLIFICATION |
7 | 0.0000007035 | Z DNA//JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS//B Z TRANSITION |
8 | 0.0000006239 | FLUOROQUINOLONES//CIPROFLOXACIN//QUINOLONES |
9 | 0.0000006115 | BREAST CANCER//ACCELERATED PARTIAL BREAST IRRADIATION//PARTIAL BREAST IRRADIATION |
10 | 0.0000005382 | BINUCLEATED LYMPHOCYTES//HUMANIZED MICE//CHEMOSENSITIVITY TEST |